Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary: Objective: Brivaracetam (BRV) and levetiracetam (LEV) are effective antiepileptic drugs that bind selectively to the synaptic vesicle 2A (SV 2A) protein. However, BRV differs from LEV in that it exhibits more potent and complete seizure suppression in animal models including in amygdala‐kindled mice, where BRV afforded nearly complete seizure suppression. This raises the possibility that aside from potency differences, BRV and LEV may interact differently with the SV 2A protein, which is not apparent in radioligand‐binding competition studies. In this study, we used a recently identified SV 2A allosteric modulator, UCB 1244283, that appears to induce conformational changes in SV 2A, to probe the binding properties of labeled BRV and LEV. Methods: Radioligand binding studies were carried out using [3 H]BRV and [3 H]LEV. Studies were performed in membranes from both recombinant cells expressing human SV 2A protein and human brain tissue. Results: The modulator increased the binding of both radioligands but by different mechanisms. For [3 H]BRV, the increase was driven mainly by an increase in affinity, whereas for [3 H]LEV, the increase was due to an increase in the number of apparent binding sites. Kinetic studies confirmed this differential effect. Significance: These studies suggest that LEV and BRV may act at different binding sites or interact with different conformational states of the SV 2A protein. It is possible that some of the pharmacologic differences between BRV and LEV could be due to different interactions with the SV 2A protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“It is notable that the SV2A protein was shown to bind the antiepileptic drugs (AEDs) levetiracetam(3) (LEV) and brivaracetam(4) (BRV), and was also shown to be the molecular target of their anticonvulsant activity.(5) A strong positive correlation has been demonstrated between anticonvulsant potency in animal models a…”
BackgroundAbnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 1×
“Changes in SV2A expression have been shown to alter glutamatergic and c-aminobutyric acid (GABA)ergic transmission; consequently, in hippocampal slices from SV2Aand SV2A/B-knockout mice, the frequency and amplitude of spontaneous inhibitory postsynaptic currents (IPSCs) were decreased, without changes in mini-IPSCs.(1…”
BackgroundSV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256
Synaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Self-citationGillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Self-citationSV2 regulates neurotransmitter release via multiple mechanisms
Nowack, A., Yao, J., Custer, K. L., & Bajjalieh, S. M. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00259.2010 · Cited by 138 · cited 1×
“This reduced release probability occurs after vesicle docking and before formation of the SNARE (soluble N-ethylmaleimidesensitive fusion) complex, suggesting that SV2A contributes to the priming of vesicles for release.(11) Changes in SV2A expression have been shown to alter glutamatergic and c-aminobutyric acid (GAB…”
BackgroundSynaptic vesicle protein 2A: basic facts and role in synaptic function
Mendoza‐Torreblanca, J. G., Vanoye‐Carlo, A., Phillips‐Farfán, B. V., Carmona‐Aparicio, L., & Gómez‐Lira, G. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12360 · Cited by 124
Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Nowack, A., Malarkey, E. B., Yao, J., Bleckert, A., Hill, J., & Bajjalieh, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029560 · Cited by 81 · cited 1×
“It has also been shown that LEV reverses the synaptic deficits produced by overexpression of the SV2A protein.(7) These data suggest that the incidence of seizures are affected by both increased and decreased expression of SV2A and are reduced by treatment with LEV.”
Background
Cited by
Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy
Chen, B., Choi, H., Hirsch, L. J., Katz, A., Legge, A., Buchsbaum, R., & Detyniecki, K. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.08.039 · Cited by 399
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
Self-citationLevetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
Levetiracetam and brivaracetam: A review of evidence from clinical trials and clinical experience
Steinhoff, B. J., & Staack, A. M. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419873518 · Cited by 99
Okada, M., Fukuyama, K., Shiroyama, T., & Ueda, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111462 · Cited by 28
Fukuyama, K., & Okada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094473 · Cited by 22
“Modulation of the function of synaptic vesicle protein type 2A (SV2A) has been considered to play an important role in the suppression of epileptic seizure, since highaffinity SV2A-binding compounds, levetiracetam and brivaracetam, are first-line antiseizure drugs [1,2].”
BackgroundKlein, P., & Bourikas, D. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02876-z · Cited by 21
“Evidence from radioligand studies suggests that BRV and LEV act at different binding sites or interact with different conformational states of the SV2A protein [12].”
BackgroundPresynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
“A radioligand binding study revealed that levetiracetam and brivarace-tam may interact differently with the SV2A protein bind - ing sites or interact with different conformational states of this protein [58].”
BackgroundMittal, A., Martin, M. F., Provins, L., Hall, A., Ledecq, M., Wolff, C., Gillard, M., Horanyi, P. S., & Coleman, J. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2510239122 · Cited by 7
Self-citation
Metadata
- Authors
- Wood, M. D., & Gillard, M.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2016-12-24
- Volume
- 58
- Issue
- 2
- Pages
- 255-262
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2562398824
- Cited by
- 101
- References
- 9
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.